The estimated window period for the combined BED/Ax-AI algorithm was 267 days (SE 64.8).
Further, the approach does not provide an exact date of diagnosis; it does, however, provide for an estimated window based on the duration of time used to look for the various claims.
In addition, TACs that were calculated based only on animal organs (i.e., no extrapolation to human values) were used to calculate additional dose estimates to provide an estimation window for the human dosimetry (referred to as 'NE' for no extrapolation).
For peptides that were identified in one sample, the regression of the identified peptide's MS/MS scan number is used to estimate a window for the same peptide in the other samples and a matching chromatographic peak was identified within that time range.
These values were then used via further finite element analysis to extrapolate to DEMO relevant monoblock designs and estimate the maximum power handling achievable based on estimated temperature windows for all component elements of the design.
It must be emphasized that this is a good result considering that the estimated target windows for our MeDIP-seq analysis is >800 bp (300 bp analysis windows overlapping 225 250 bp fragments), while bisulfite pyrosequencing targets single nucleotides.
Most notably, recombination rates can only be estimated for windows of approximately constant genetic width, but not for windows of constant physical width.
Estimated mean window periods for the BED and Ax-AI assays among participants in the prospective sample were substantially longer than published window period values (330 vs. 155 days for BED, and 310 vs. 180 days for Ax-AI).
Using data from these participants whose infection status changed from RI to LTI during follow-up, and excluding data from 2 seroconverters who reported initiating ART since their HIV diagnosis, the estimated mean window periods for BED and Ax-AI were approximately 330 (SE 84.1) and 310 (SE 69.9) days, respectively.
Section 3 presents the general equations for cross bilinear product in time-lag domain for both auto-terms and duplicated terms together with the LLAC algorithm for estimating the adaptive window for the PSK class signals.
The aim of this study was to use this model to evaluate the efficacy and safety of different doses of rivaroxaban compared with other anticoagulants, thereby estimating a therapeutic window for rivaroxaban.
